EGFR and non-small cell lung carcinoma: In previous subgroup analyses of the large neoadjuvant immunotherapy clinical trial KEYNOTE-671 in NSCLC (17), patients with EGFR mutations exhibited favorable clinical outcomes compared with those with wild-type or unknown EGFR status.